CPB Stock Slips As Wall Street Turns Cautious On 2027

The Campbell’s Company stocks have been trading down by -7.13 percent amid investor concerns over weakening consumer demand.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CPB

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For CPB Traders

Evercore ISI cut Campbell Soup’s price target to $22 from $23, citing persistent Snacks weakness, roughly 6% inflation, and heavier growth spending that pulled down FY27 expectations.
TD Cowen nudged its CPB target to $22 from $20 but kept a Hold rating and trimmed estimates below consensus, flagging FY27 as an “investment year” with sales declines and margin pressure.
Stephens lowered its CPB target from $21 to $20, warning of continued organic sales declines in Snacks through FY26–FY27 ahead of fiscal Q4 earnings.
UBS reiterated a Sell on CPB, lifting its target slightly to $18 while cutting Q4 and FY27 EPS on weaker consumption, inflation, and a tougher FY27 profit outlook.
RBC Capital kept a Sector Perform on CPB with a $21 target versus a roughly $23.63 share price, highlighting weak consumer health, soft retailer trends, and Rao’s as the lone bright spot.

Live Update At 15:04:27 EDT: On Thursday, September 03, 2026 The Campbell’s Company stock [NASDAQ: CPB] is trending down by -7.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CPB is trading in the low-$20s, and the tape shows pressure building. Over the last couple of weeks, Campbell Soup has faded from the $24 area down near $22, with the latest daily close around $22.09. That steady drift lower tells traders the market is quietly repricing the story ahead of fiscal Q4 and FY27 guidance.

Intraday action reinforces that view. CPB opened strong near $22.32, briefly tested $22.61, then spent the day grinding down toward $21.15 before clawing back just above $22. That wide intraday range and late bounce point to active trading and headline sensitivity, not complacency.

More Breaking News

On fundamentals, CPB still throws off solid cash and profit. Revenue runs around $10.25B, with gross margin near 63.4% and EBIT margin about 8.9%. A P/E near 11.7 and price‑to‑sales around 0.71 screen “cheap,” but leverage is real: debt‑to‑equity sits at 1.74 and the current ratio below 1. Management is covering a rich dividend — roughly a 6.5% yield — yet free cash flow last quarter was only about $29M, with heavy working‑capital drag. For traders, that mix says value on paper, but not much room for execution mistakes.

Why Traders Are Watching CPB Now

CPB is sitting in that uncomfortable zone where the chart is soft and the Street narrative keeps getting a little worse every week. The latest round of notes from Evercore ISI, UBS, RBC Capital, TD Cowen, and Stephens all circle the same problem: the Snacks segment and a stubborn inflation backdrop are squeezing the long‑term earnings story.

Evercore ISI cut its Campbell Soup target to $22, right on top of where CPB trades, while only calling the stock In Line. That tells traders the firm doesn’t see a big reward for stepping in here. Their rationale is clear — ongoing Snacks sales weakness and roughly 6% inflation, plus the need to spend more on growth, drag down FY27 expectations. When even neutral coverage trims long‑term targets, upside looks capped unless Snacks turns.

UBS is even more direct. It reiterated a Sell on CPB, nudging its target to just $18 and cutting Q4 and FY27 EPS estimates. UBS flags weaker consumption, pressure across snack categories, and higher reinvestment and incentive costs as key headwinds. It also warns FY27 earnings could see a “meaningful” drop in operating profit. For short‑biased traders, that type of language is a green light to keep CPB on the watchlist.

RBC Capital and Stephens add weight to the bear case. RBC’s $21 target sits below the current CPB price, and its revenue forecasts sit under the low end of company guidance. It calls out weak consumer health and soft retailer trends hitting Meals & Beverages and Snacks, with Rao’s as the only real winner. Stephens trims its target to $20 and expects organic Snacks declines through FY26–FY27. Put together, multiple firms see multi‑year volume pressure — exactly the kind of overhang that keeps a defensive name like CPB stuck in a range, with every rally vulnerable to disappointments.

Conclusion

For active traders, CPB is a classic “cheap for a reason” setup. The stock trades at a low earnings multiple, throws off a big dividend, and carries powerful legacy brands. But the recent price action, sliding from the mid‑$24s to near $22 while targets from Evercore ISI, UBS, RBC Capital, TD Cowen, and Stephens cluster around $18–$22, shows how cautious the Street has become on Campbell Soup’s FY27 path.

The fundamental picture backs that caution. CPB is generating solid gross margins, yet margin compression, Snacks volume declines, and elevated inflation are chipping away at operating leverage. Balance‑sheet debt and a sub‑1 current ratio limit flexibility, even as the company spends to reignite growth. UBS sees a tough upcoming Q4 and warns that FY27 estimates remain too high. RBC’s revenue numbers sit below guidance. Those are not the kind of cross‑currents that usually power sustained breakouts.

That does not mean CPB is untradeable. Far from it. A crowded short base, defensive sector flows, or a cleaner‑than‑feared Q4 print could spark sharp squeezes. But those are trading setups, not long‑term comfort blankets. As Tim Sykes likes to say, “Trade the price action, not the story — and always respect the risk.” And in the same spirit of risk‑first thinking, As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.”. For Campbell Soup and CPB, the story right now is one of pressure, skepticism, and tight margins. Traders who stay disciplined, watch the levels, and cut losses fast will be in the best position to react when the next headline hits.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!